CRVO News & Events

CervoMed announced that, at the AD/PD 2026 Conference in Copenhagen, Denmark, investigators will present new analyses from the Phase 2b RewinD-LB clinical trial of neflamapimod, being developed by CervoMed, for the treatment of dementia with Lewy bodies, or DLB. The new data analyses reinforce that neflamapimod, which targets the neuroinflammation and synaptic dysfunction associated with DLB, has the potential to slow disease progression by acting on the underlying disease biology. New analyses show DLB patients with lower plasma pTau181 levels - indicating an earlier stage of disease and absence of Alzheimer's disease co-pathology - experienced greater clinical benefit with neflamapimod in Phase 2b clinical trial. PK/PD analyses of Phase 2b clinical data provide further insight into the drug plasma concentration levels of neflamapimod associated with a clinical effect. Findings further support neflamapimod's potential to target the underlying cause of disease in DLB and the company's patient enrichment strategy and dosing regimen for planned Phase 3 trial. The analyses presented at AD/PD reveal a consistently improving treatment effect in multiple clinical end points at progressively lower plasma pTau181 levels, which are associated with a higher percentage of DLB patients without AD co-pathology.

Believes its cash, cash equivalents, and marketable securities on hand will enable the company to fund its planned operating expenses and capital expenditure for approximately six months from now. "CervoMed made significant strides in 2025 and early 2026 with its lead neflamapimod program in dementia with Lewy bodies. We reported positive and supportive Phase 2b RewinD-LB data at the 18th Clinical Trials on Alzheimer's Disease Conference, obtained alignment with the FDA and other global regulators on the design of our planned Phase 3 trial design in patients with DLB, and selected the neflamapimod formulation, dose and dosing regimen that will be used in the planned Phase 3 trial," said CEO John Alam. "We are now looking ahead to a catalyst-driven 2026, including initiation of the planned Phase 3 trial evaluating neflamapimod in DLB in the second half of 2026, subject to available financing. In addition, we expect to report initial topline Phase 2a results from our other programs evaluating neflamapimod in both ischemic stroke recovery and the non-fluent variant primary progressive aphasia, along with initiation of the EXPERTS-ALS trial in amyotrophic lateral sclerosis, all during the second half of 2026 as well."